What did @kelly_garis actually say?
Kelly says she lost 16 pounds over five full weeks on tirzepatide, is now heading into week six, and injected "16.67 units" of what she calls a peptide from a website called certified-pept.com. She also mentions splitting her weekly dose into two separate shots the prior week and deciding it wasn't worth the extra injection. She's promoting a 15% discount code for that supplier.
A few things immediately stand out. She's not using a brand-name tirzepatide product like Zepbound or Mounjaro. She's drawing up units from what sounds like a vial, which is the hallmark of compounded or gray-market peptide sourcing. She's also openly promoting a third-party supplier with an affiliate code, which is worth flagging for anyone watching this as medical guidance.
Does the science back this up?
The weight loss rate she describes is plausible but sits at the high end of what clinical trials show, especially early on. It is not impossible, but context matters.
The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) is the landmark tirzepatide weight loss study. At the highest dose (15 mg), participants lost an average of 20.9% of body weight over 72 weeks. Early-phase weight loss in that trial was faster, partly because of water weight and rapid appetite suppression in the first few weeks. Losing 16 pounds in five weeks is aggressive but not outside the range of early responders, particularly if someone has significant water retention to shed or was already eating substantially less.
The hunger increase she mentions around her menstrual cycle also has biological backing. Research on hormonal fluctuations and appetite, including work by Davidsen et al. (2007, Acta Obstetricia et Gynecologica Scandinavica), confirms that progesterone in the luteal phase can increase appetite and caloric intake. Her observation here is reasonable.
What did they get wrong (or right)?
She got the hunger-and-cycle connection right. That part is grounded in real physiology.
What she got wrong, or at minimum glossed over, is more serious. She is sourcing tirzepatide from a website called certified-pept.com and calling it a "peptide" rather than a medication. Compounded tirzepatide from licensed compounding pharmacies became legally available during an FDA shortage period, but the FDA has since removed tirzepatide from its shortage list as of late 2024, which changes the legal and safety picture considerably. Gray-market peptide suppliers are a separate category entirely. They operate outside pharmacy regulation, and their products have no guaranteed potency, sterility, or identity verification.
Her dose framing is also problematic. Saying she draws "16.67 units" and rounds up to 17 sounds precise, but units mean different things depending on concentration. Without knowing the vial's concentration, those numbers are meaningless to viewers trying to replicate her dose, and potentially dangerous.
Splitting her weekly dose into two injections is not a standard protocol for tirzepatide, which is designed as a once-weekly injection. There is no published evidence supporting split dosing as a strategy to improve tolerability or efficacy.
What should you actually know?
Tirzepatide is a legitimate, FDA-approved dual GIP and GLP-1 receptor agonist. The clinical evidence for its weight loss effects is strong. But the drug someone buys from a peptide website is not the same product studied in clinical trials, and treating them as equivalent is a mistake.
The FDA has issued warnings about compounded semaglutide and tirzepatide products specifically because of dosing errors and contamination risks. A 2024 FDA safety communication flagged reports of hospitalizations related to compounded GLP-1 products, including cases tied to unit-based dosing confusion.
- Tirzepatide is approved by the FDA as Zepbound (weight management) and Mounjaro (type 2 diabetes) in fixed-dose pens, not vials.
- Purchasing tirzepatide from unregulated peptide suppliers carries real risks: unknown purity, incorrect concentration, and no pharmacist oversight.
- Early weight loss on GLP-1 class drugs often includes water weight and is not fully representative of long-term fat loss trends.
- If you are interested in tirzepatide, the path is through a licensed prescriber and a regulated pharmacy, not a discount code from a TikTok influencer.
Should you take medical cues from this video?
No. Kelly seems genuine, and her experience may be real. But she is not a medical professional, her supplier is unverified, and her dose framing is not replicable in any safe or meaningful way. The 15% discount code is a financial incentive that should make any viewer think twice about how objective this content actually is. Weight loss results on GLP-1 medications vary significantly based on starting weight, dose, adherence, and individual metabolism. Her results are hers. They are not a prediction for anyone else.